Breaking News, Collaborations & Alliances

Teva and mAbxience Enter Strategic Licensing Agreement for Biosimilar Candidate

Signals a step in mAbxience's global expansion strategy and advances Teva’s goal to expand its biosimilar pipeline through business development.

Author Image

By: Charlie Sternberg

Associate Editor

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, have entered a strategic licensing agreement for a biosimilar candidate currently in development for the treatment of multiple oncology indications.   The licensing agreement covers multiple global markets, including in Europe and the United States. Under the terms of the agreement, mAbxience will leverage it...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters